Deadline: 29-Jul-25
The Pfizer Independent Research Grant Program aims to support research proposals that address data gaps concerning Invasive Mold Infectionsin in real-world settings.
This initiative seeks to advance clinical understanding of isavuconazole within the treatment landscape.
The goal is to address critical knowledge gaps and develop evidence-based strategies to optimize treatment with isavuconazole, improve patient outcomes, and reduce morbidity and mortality associated with these infections.
Areas of Interest
- Primary Area of Interest:
- Infectious Disease – Fungal – RES
- General Area of Interest
- Projects to be considered for Pfizer support will focus on the following areas:
- Real-world evidence studies leveraging quality data sources for description and analysis of Isavuconazole treatment outcomes. Data sources can be: demographics data, surveillance systems, electronic health records, clinical and lab registries, patient reported clinical outcomes, wearables, or any other good quality data types able to provide reliable results.
- The burden of the disease across different populations, including onco-hematology, solid organ transplant, immunosuppressant usage, post-viral infections, intensive care settings, chronic obstructive pulmonary diseases, and presence of co-infections between Invasive Aspergillosis and Invasive Mucormycosis.
- Isavuconazole as first line therapy in onco-hematology, solid organ transplant, immunosuppressant usage, post-viral infections, intensive care settings, chronic obstructive pulmonary diseases, CAR-T cell recipients, etc.) and presence of co-infections between Invasive Aspergillosis and Invasive Mucormycosis.
- Isavuconazole and Central Nervous System (CNS) infections and outcomes.
- Isavuconazole and therapeutic dosage monitoring in severely ill patients and special populations such as, but not restricted to: ECMO, Renal replacement therapy, obese, hypoalbuminemic patients, pediatric (efficacy and safety beyond plasma levels).
- Drug-drug interactions management with isavuconazole in real-world settings in adult and pediatric settings.
- Breakthrough infections after azol treatment.
- Projects to be considered for Pfizer support will focus on the following areas:
Funding Information
- Individual projects requesting up to $30,000 USD will be considered. The estimated total available budget related to this RFP is $100,000 USD.
Duration
- Maximum project length is 10 months.
Geographic Focus
- Australia, Germany, Israel, Italy, Spain, and Switzerland
Eligibility Criteria
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. They strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
For more information, visit Pfizer.
